Wire Stories
Regenacy Announces the Formation of a Joint Venture with 3E Bioventures to Develop Ricolinostat in China and the Start of a U.S. Phase 2 Study in Painful Diabetic Peripheral Neuropathy
WALTHAM, Mass.–(BUSINESS WIRE)–Regenacy Pharmaceuticals, a clinical-stage biopharmaceutical company developing breakthrough treatments for diabetic and other peripheral neuropathies, and 3E Bioventures Capital, a...